Filing Details
- Accession Number:
- 0001085037-22-000028
- Form Type:
- 13D Filing
- Publication Date:
- 2022-06-01 20:00:00
- Filed By:
- Schutte Andrew
- Company:
- Replicel Life Sciences Inc.
- Filing Date:
- 2022-06-02
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Andrew Schutte | 8,351,535 | 8,351,535 | 8,351,535 | 18.55% |
Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
(Amendment No. 2)
(Amendment No. 2)
Under the Securities Exchange Act of 1934
| REPLICEL LIFE SCIENCES INC. |
| (Name of Issuer) |
| Common Shares without par value |
| (Title of Class of Securities) |
| 76027P400 |
| (CUSIP Number) |
| copy to: Andrew Schutte 2604 River Green Circle Louisville, KY 40206 502.548.2713 |
| (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
| May 4, 2022 |
| (Date of Event which Requires Filing of this Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition
that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. [ ]
Note:
Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on
this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
SCHEDULE 13D
| CUSIP No. | 76027P400 |
| 1 | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) | |||
| Andrew Schutte | ||||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | |||
| (a) [ ] (b) [ ] | ||||
| 3 | SEC USE ONLY | |||
| | ||||
| 4 | SOURCE OF FUNDS (See Instructions) | |||
| PF | ||||
| 5 | CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E) | |||
| [ ] | ||||
| 6 | CITIZENSHIP OR PLACE OF ORGANIZATION | |||
| United States | ||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER | ||
| 8,351,535(1) | ||||
| 8 | SHARED VOTING POWER | |||
| Nil | ||||
| 9 | SOLE DISPOSITIVE POWER | |||
| 8,351,535(1) | ||||
| 10 | SHARED DISPOSITIVE POWER | |||
| Nil | ||||
| 11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | |||
| 8,351,535 common shares(1) | ||||
| 12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) | |||
| [ ] | ||||
| 13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) | |||
| 18.55%(2) | ||||
| 14 | TYPE OF REPORTING PERSON (See Instructions) | |||
| IN | ||||
| (1) | Consists of the following securities: (i) 6,079,604 common shares held directly; (ii) 303,030 common shares issued on the conversion of class A preference shares at a
conversion price of $0.33 per class A preference share, (iii) 355,000 stock options, each of which is exercisable into one common share, of which 30,000 are exercisable at a price of $0.43 per common share until July 30, 2023 and 325,000 are
exercisable at a price of $0.40 per common share until June 14, 2026 and (iv) 1,613,901 warrants, each of which is exercisable into one common share, of which 562,750 are exercisable at a price of $0.36 per common share until July 15, 2023
and 1,051,151 are exercisable at a price of $0.40 per common share until May 4, 2025. |
| (2) | Calculated based on the aggregate of 45,021,496 common shares, which consists of: (i) 42,749,565 common shares outstanding as of May 4, 2022, (ii) 303,030 common shares
that may be issuable on conversion of class A preference shares, (iii) 355,000 common shares that may be issuable on exercise of options and (iv) 1,613,901 common shares that may be issuable on exercise of warrants, all within sixty days,
pursuant to Rule 13d-3 of the Act. |
This Schedule 13D is being filed on behalf of Andrew Schutte (the “Reporting Person”) relating to the common shares of
RepliCel Life Sciences Inc., a corporation existing under the laws of the Province of British Columbia (the “Issuer”).
Item 1. Security and Issuer
This Statement relates to the common shares (the “Shares”) of the Issuer. The principal executive offices of the Issuer are located at 900
– 570 Granville Street, Vancouver, BC V6C 3P1.
Item 2. Identity and Background
This Statement is filed by the Reporting Person.
The Reporting Person, a director of the Issuer, has a residence address at 2604 River Green Circle, Louisville, KY 40206 and is a citizen of the United States.
The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar
misdemeanors).
The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of
competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any
violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Considerations
On May 17, 2021, the Report Person acquired 29,037 Shares at a deemed price of CDN $0.18 pursuant to payment of accrued dividends.
Pursuant to a debt settlement and subscription agreement dated March 30, 2021, the Reporting Person acquired 216,693 Shares in settlement of CDN $83,426.58 worth of debt owed to the Reporting Person, which shares were issued on June 2, 2021.
On June 14, 2021, the Reporting Person was granted 325,000 stock options, each of which is exercisable into one Share, at a price of
CDN$0.40 per Share until June 4, 2026.
Pursuant to a subscription agreement dated May 4, 2022, the Reporting Person purchased 2,102,303 units (each, a “Unit”) of the Issuer at a
price of CDN$0.18 per Unit in a private transaction for total consideration CDN$378,414.50. Each Unit consists of one Share and one-half of one non-transferable share purchase warrant (each, a “Warrant”). Each Warrant entitles the Reporting Person
to acquire one Share (each, a “Warrant Share”) at a price of CDN$0.40 per Warrant Share until May 4, 2025.
Item 4. Purpose of Transaction
The Reporting Person acquired the securities for investment purposes, for settlement of accrued dividends and for settlement of debt owed to
the Reporting Person, but may transfer or sell such Shares as necessary and in accordance with applicable securities laws.
As of the date hereof, except as described in this Schedule 13D, the Reporting Person does not have any plans or proposals which relate to
or would result in:
| • | the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; | |
| • | an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; | |
| • | a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; | |
| • | any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors
or to fill any existing vacancies on the board; | |
| • | any material change in the present capitalization or dividend policy of the Issuer; | |
| • | any other material change in the Issuer's business or corporate structure, including but not limited to, if the Issuer is a registered closed-end
investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940; | |
| • | changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the
Issuer by any person; | |
| • | causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an
inter-dealer quotation system of a registered national securities association; | |
| • | a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or | |
| • | any action similar to any of those enumerated above. |
Item 5. Interest in Securities of the Issuer
The aggregate number and percentage of Shares beneficially owned by the Reporting Person is 8,351,535 Shares (including: 6,079,604 Shares
held directly; (ii) 303,030 Shares issued on the conversion of class A preference shares at a conversion price of $0.33 per class A preference share, (iii) 355,000 stock options, each of which is exercisable into one Share, of which 30,000 are
exercisable at a price of $0.43 per Share until July 30, 2023 and 325,000 are exercisable at a price of $0.40 per Share until June 14, 2026, and (iv) 1,613,901 warrants each of which is exercisable into one Share, of which 562,750 are exercisable at
a price of $0.36 per common share until July 15, 2023 and 1,051,151 are exercisable at a price of $0.40 per Share until May 4, 2025), or 18.55% of the Issuer, based on 45,021,496 Shares outstanding as of May 4, 2022, which consists of: (i)
42,749,565 Shares outstanding as of May 4, 2022, (ii) 303,030 Shares that may be issuable on conversion of class A preference shares, (iii) 355,000 Shares that may be issuable on exercise of options and (iv) 1,613,901 Shares that may be issuable on
exercise of warrants, all within sixty days, pursuant to Rule 13d-3 of the Act.
The Reporting Person has the sole power to vote or direct the
vote, and to dispose or direct the disposition, of 8,351,535 Shares.
Other than as described in Item 3 above, the Reporting Person has
not effected any transaction in the Shares in the past sixty days.
No person, other than the Reporting Person, is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the 8,351,535 Shares.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
Except as set forth above or set forth in the exhibits and this Schedule 13D, there are no contracts, arrangements, understandings or
relationships between reporting persons and any other person with respect to any securities of the Issuer.
Item 7. Material to Be Filed as Exhibits
None.
Signature
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this
statement is true, complete and correct.
| Dated: June 2, 2022 | /s/ Andrew Schutte Signature |
| Andrew Schutte Name | |
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the
statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the
statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath
his signature.
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).